Warner Chilcott (NASDAQ: WCRX)‘s stock had its “buy” rating reiterated by Canaccord Genuity in a research note issued on Monday.
Separately, analysts at Needham & Company reiterated a “hold” rating on shares of Warner Chilcott in a research note to investors on Monday. Analysts at Citigroup (NYSE: C) reiterated a “buy” rating on shares of Warner Chilcott in a research note to investors on Tuesday, December 27th. They now have a $24.00 price target on the stock. Also, analysts at Barclays Capital (NYSE: BCS) initiated coverage on shares of Warner Chilcott in a research note to investors on Friday, December 9th. They set an “equal weight” rating and a $18.00 price target on the stock.
Warner Chilcott PLC, formerly Warner Chilcott Limited, is a Bermuda-based specialty pharmaceutical company focused on the women’s healthcare and dermatology segments of the United States pharmaceutical market. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products. On October 30, 2009, the Company acquired The Procter & Gamble Company’s global branded prescription pharmaceutical business. In October 2010, the Company announced that it has completed its acquisition of the United States rights to Enablex from Novartis AG.
Warner Chilcott traded down 0.48% on Monday, hitting $16.61. Warner Chilcott has a 1-year low of $12.90 and a 1-year high of $25.92. The stock has a 50-day moving average of $15.80 and a 200-day moving average of $16.86. The company has a market cap of $4.221 billion and a price-to-earnings ratio of 43.92.